diethyl (E)-2-(4-carboxyphenyl)vinylphosphonate | 251571-00-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: diethyl (E)-2-(4-carboxyphenyl)vinylphosphonate
• 英文别名: 4-[(E)-2-diethoxyphosphorylethenyl]benzoic acid
• CAS: 251571-00-3
• 化学式: C₁₃H₁₇O₅P
• 分子量: 284.249
• InChiKey: FPSGKXYHJQKBKN-MDZDMXLPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-羟基苯甲脒盐酸盐 、 diethyl (E)-2-(4-carboxyphenyl)vinylphosphonate 在 吡啶 、 N,N'-二环己基碳二亚胺 作用下， 反应 17.0h， 生成 4-[(E)-2-(Diethoxy-phosphoryl)-vinyl]-benzoic acid 4-carbamimidoyl-phenyl ester
  参考文献：
  名称：

  New serine protease inhibitors with leukotriene B4 (LTB4) receptor binding affinity

  摘要：

  A series of new trypsin-like serine protease inhibitors, 1, 2 and 7-23, containing amidinobenzene moiety was found to show potent LTB4-receptor affinity. Among them, compounds 1 and 2 were found to be LTB4 receptor antagonists based on an inhibition assay of human polymorphonuclear neutrophil (PMN) intracellular calcium mobilization induced by LTB4. Compounds 1 and 2, which satisfy the reported structural requirements for good oral activity, are expected to show a balanced dual mode of action, i.e., protease inhibitory activity and LTB4 receptor antagonist activity, in vivo. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(97)00036-9
• 作为产物：
  描述：

  甲基膦酸二乙酯 在 正丁基锂 、 甲基磺酰氯 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 15.5h， 生成 diethyl (E)-2-(4-carboxyphenyl)vinylphosphonate
  参考文献：
  名称：

  New serine protease inhibitors with leukotriene B4 (LTB4) receptor binding affinity

  摘要：

  A series of new trypsin-like serine protease inhibitors, 1, 2 and 7-23, containing amidinobenzene moiety was found to show potent LTB4-receptor affinity. Among them, compounds 1 and 2 were found to be LTB4 receptor antagonists based on an inhibition assay of human polymorphonuclear neutrophil (PMN) intracellular calcium mobilization induced by LTB4. Compounds 1 and 2, which satisfy the reported structural requirements for good oral activity, are expected to show a balanced dual mode of action, i.e., protease inhibitory activity and LTB4 receptor antagonist activity, in vivo. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(97)00036-9

文献信息

• Vinylbenzene derivatives
  申请人：Santen Pharmaceutical Co., Ltd.

  公开号：US06329547B1

  公开（公告）日：2001-12-11

  The present invention provides compounds represented by the following general formula [I] and salts thereof, which are useful as therapeutic agents for glaucoma, wherein R1 is H, lower alkyl or phenyl, and the phenyl can be substituted by lower alkyl, hydroxy, lower alkoxy, halogen, nitro or phenyl; R2 and R3, being the same or different, are H, halogen or lower alkyl; R4 and R5, being the same or different, are H, lower alkyl or carboxyl or ester thereof; and R6 is carboxyl or phosphono or ester thereof.

  本发明提供了以下一般式I及其盐所代表的化合物，这些化合物可用作青光眼的治疗剂， 其中R1为H、较低的烷基或苯基，苯基可由较低的烷基、羟基、较低的烷氧基、卤素、硝基或苯基取代；R2和R3，相同或不同，为H、卤素或较低的烷基；R4和R5，相同或不同，为H、较低的烷基或羧基或其酯；R6为羧基或磷酸酯或其酯。
• New serine protease inhibitors with leukotriene B4 (LTB4) receptor binding affinity
  作者：Yoshisuke Nakayama、Kazuhiko Senokuchi、Katsuhito Sakaki、Masashi Kato、Toru Maruyama、Toru Miyazaki、Hidenori Ito、Hisao Nakai、Masanori Kawamura

  DOI：10.1016/s0968-0896(97)00036-9

  日期：1997.5

  A series of new trypsin-like serine protease inhibitors, 1, 2 and 7-23, containing amidinobenzene moiety was found to show potent LTB4-receptor affinity. Among them, compounds 1 and 2 were found to be LTB4 receptor antagonists based on an inhibition assay of human polymorphonuclear neutrophil (PMN) intracellular calcium mobilization induced by LTB4. Compounds 1 and 2, which satisfy the reported structural requirements for good oral activity, are expected to show a balanced dual mode of action, i.e., protease inhibitory activity and LTB4 receptor antagonist activity, in vivo. (C) 1997 Elsevier Science Ltd.